About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
Products in R&D
Clinical Trial
Science & Technology
R&D Result
Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
Be the most trusted biotech company
Press Release
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Popular Science
Highlights
Download
Media Reports
Media Enquiry
2024-05-15
First Patient Dosed for MRCT Phase 3 Study on First-Line mCRC of Henlius Anti-PD-1 mAb Serplulimab
2024-05-14
Henlius lasofoxifene HLX78 IND Approved by NMPA
2024-05-10
Henlius Holds its first Scientific Advisory Board Meeting of 2024
2024-05-06
Henlius Dual HER2 Blockade Therapy Receives Phase 3 MRCT IND Approval from U.S. FDA
2024-04-29
Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products
2024-04-26
Henlius Trastuzumab Receives FDA Approval in the United States
2024-04-25
Henlius to Showcase Latest Results of Serplulimab at 2024 ASCO
2024-04-23
First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Novel Anti-GARP/TGF-β1 mAb HLX6018
2024-04-17
IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI for the First-Line Treatment of Locally Advanced or Metastatic Hepatocellular Carcinoma Patients Approved by NMPA
1
...
4
5
6
7
8
9
10
